Brief: Journal Of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data For Adagrasib As A Targeted Treatment For Krasg12c-Mutated Advanced Solid Tumors
26/04/2023 22:43
April 26 (Reuters) - Mirati Therapeutics Inc MRTX.O :
* JOURNAL OF CLINICAL ONCOLOGY PUBLISHES RAPID COMMUNICATION
FEATURING UPDATED CLINICAL DATA FOR ADAGRASIB AS A TARGETED
TREATMENT FOR KRASG12C-MUTATED ADVANCED SOLID TUMORS
Source text for Eikon: ID:nPn69LH9ta
Further company coverage: MRTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirati Therapeutics
See all newsBrief: European Commission Approves KRAZATI As A Targeted Treatment For Non-Small Cell Lung Cancer
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)